Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002920 · ClinicalTrials.gov registry record · Phase 3
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
NCT00002920 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 313 participants.
The verdict
NCT00002920, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
Study Summary
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ, lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II breast cancer and who are taking tamoxifen.
Interventions
- PROCEDURE adjuvant therapy
- DRUG tamoxifen citrate
- DRUG medroxyprogesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 1997-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002920
The ClinicalTrials.gov registry entry for NCT00002920 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which adjuvant therapy is the first listed.
NCT00002920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002920 about?
NCT00002920 is a clinical study titled "S9630, Medroxyprogesterone in Treating Women With Breast Cancer". RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopau...
What is the current status of trial NCT00002920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 1997-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00002920?
The interventions under investigation include: adjuvant therapy (PROCEDURE), tamoxifen citrate (DRUG), medroxyprogesterone (DRUG).
Who is sponsoring clinical trial NCT00002920?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.